Aktis Oncology (NASDAQ:AKTS) Stock Price Crosses Above 50 Day Moving Average – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS)’s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $19.13 and traded as high as $19.73. Aktis Oncology shares last traded at $19.46, with a volume of 137,186 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. William Blair assumed coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They set an “outperform” rating for the company. HC Wainwright boosted their price objective on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Finally, Weiss Ratings cut shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.

Aktis Oncology Trading Up 4.7%

The company’s 50 day simple moving average is $19.13.

Aktis Oncology (NASDAQ:AKTS) last posted its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The company had revenue of $1.87 million for the quarter. On average, analysts predict that Aktis Oncology will post -1.62 earnings per share for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.